Thus, the clinical importance of PSMA PET imaging lies in its ability to redefine staging via its sensitivity to detect metastatic disease in patients with previously diagnosed nonmetastatic CRPC (37). The gene discussed is FOLH1; the disease is metastatic neoplasm.